Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147413 | 0.82 | MEN1 (0.69) | GAAALDH1A1POLBRAB9AKMT2A | |
| SCHEMBL24838582 | 0.78 | KMT2A (0.49) | GAAALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL29017338 | 0.77 | ALDH1A1 (0.79) | GAAALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL13858960 | 0.77 | KDM4E (0.46) | GAAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL4904341 | 0.75 | GAA (0.52) | GAAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL4896945 | 0.75 | GAA (0.52) | GAAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL20148004 | 0.74 | MEN1 (0.66) | GAAALDH1A1POLBRAB9AKMT2A | |
| SCHEMBL20008961 | 0.74 | OPRL1 (0.61) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL27337753 | 0.73 | GAA (0.51) | GAAALDH1A1POLBNPC1RAB9A | |
| SCHEMBL4896837 | 0.73 | GAA (0.51) | GAAALDH1A1POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | GAA 339/4885ALDH1A1 2101/4885POLB 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.